Gender issues in multiple sclerosis

References

• Papers of special note have been highlighted as:
   Google Scholar
• of interest
   Google Scholar
• of considerable interest
   Google Scholar
• Keegan BM, Noseworthy JH. Multiple sclerosis. Ann. Rev. Med. 53, 285302 (2002).
   Web of Science ®Google Scholar
• Good recent review of multiple sclerosis.
   Google Scholar
• Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand, are the determinants genetic or environmental? J. Neurol. Neurosurg. Psychiatry 53, 903905 (1990).
   Google Scholar
• Forbes RB, Wilson SV, Swingler RJ. The prevalence of multiple sclerosis in Tayside, Scotland, do latitudinal gradients really exist? J. Neurol. 246, 10331040 (1999).
   Google Scholar
• Forbes RB, Swingler RJ. Estimating the prevalence of multiple sclerosis in the United Kingdom by using capture recapture methodology. Am. J. Epidemiol. 149, 10161024 (1999).
   Web of Science ®Google Scholar
• Elian M, Dean G. Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies. J. Neurol. Neurosurg. Psychiatry 50, 327332 (1987).
   Web of Science ®Google Scholar
• van der Mei I, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168174 (2001).
   Web of Science ®Google Scholar
• Compston A. Risk factors for multiple sclerosis, race or place? J. Neurol. Neurosurg. Psychiatry 53, 821823 (1990).
   Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis, a geographically based study I. Clinical course and disability. Brain 112, 133146 (1989).
   Google Scholar
• Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin. Neurol. Neurosurg. 103, 111 (2000).
   Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis, guidelines for research protocols. Ann. Neurol. 13, 227231 (1983).
   Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis, guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121127 (2001).
   Web of Science ®Google Scholar
• Dalton CM, Brex PA, Miszkiel KA et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann. Neurol. 52, 4753 (2002).
   Web of Science ®Google Scholar
• McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 113, 12691289 (1990).
   Google Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS, consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206, 165171 (2003).
   Google Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions, implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707717 (2000).
   Web of Science ®Google Scholar
• Important paper about modern concepts of the pathology and classifiaction of multiple sclerosis.
   Google Scholar
• Allen IV, McQuaid S, Mirakhur M, Nevin G. Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol. Sci. 22, 141144 (2001).
   Web of Science ®Google Scholar
• Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal appearing white matter in a patient with acute MS. Neurology 57, 12481252 (2001).
   Google Scholar
• Emphasizes the loss of axons that may be found in multiple sclerosis.
   Google Scholar
• Rudick RA. Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications. J. Neuroophthalmol. 21, 279283 (2001).
   Web of Science ®Google Scholar
• Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult. Scler. 8, 9397 (2002).
   Google Scholar
• Vukusic S, Confavreux C. Primary and secondary progressive multiple sclerosis. J. Neurol. Sci. 206, 153155 (2003).
   Web of Science ®Google Scholar
• Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3, 291301 (2002).
   Google Scholar
• Schwartz M, Kipnis J. Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity, a paradigm shift. Neuroscientist 8, 405413 (2002).
   Web of Science ®Google Scholar
• Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis, from immunosuppression to neuroprotection. Trends Pharmacol. Sci. 24, 131138 (2003).
   Google Scholar
• Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3, 705714 (2002).
   Google Scholar
• OConnor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis, possible roles of T and B-lymphocytes in immunopathogenesis. J. Clin. Immunol. 21, 8192 (2001).
   Web of Science ®Google Scholar
• Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis, the role of T-cells. Curr. Opin. Neurol. 12, 309321 (1999).
   Web of Science ®Google Scholar
• Archelos JJ, Storch MK, Hartung HP. The role of B-cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47, 694 706 (2000).
   Google Scholar
• Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin-2-responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973984 (1994).
   Google Scholar
• Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120, 14471460 (1997).
   Web of Science ®Google Scholar
• Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases, a comparative study. Brain 122, 20472056 (1999).
   Web of Science ®Google Scholar
• Mata S, Lolli F, Soderstrom M, Pinto F, Link H. Multiple sclerosis is associated with enhanced B-cell responses to the ganglioside GD1a. Mult. Scler. 5, 379388 (1999).
   Google Scholar
• Pender MP, Csurhes PA, Wolfe NP et al. Increased circulating T-cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 10, 6366 (2003).
   Google Scholar
• Waubant E, Goodkin D, Bostrom A et al. IFN- lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60, 5257 (2003).
   Web of Science ®Google Scholar
• Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD. Cerebral atrophy and disability in relapsingremitting and secondary progressive multiple sclerosis over four years. Mult. Scler. 9, 2127 (2003).
   Google Scholar
• Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64\(Suppl. 1), S102S105 (1998).
   Google Scholar
• Losseff NA, Webb SL, ORiordan JI et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701708 (1996).
   Google Scholar
• Lachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult. Scler. 7, 327334 (2001).
   Google Scholar
• Rovaris M, Rocca MA, Filippi M. Magnetic resonance-based techniques for the study and management of multiple sclerosis. Br. Med. Bull. 65, 133144 (2003).
   Google Scholar
• Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 6, 8891 (2000).
   Google Scholar
• Pender MP, Stanley GP, Yoong G, Nguyen KB. The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A. Acta Neuropathol. Berl. 80, 172183 (1990).
   Web of Science ®Google Scholar
• Hammond SR, de Wytt C, Maxwell et al. The epidemiology of multiple sclerosis in Queensland, Australia. J. Neurol. Sci. 80, 185204 (1987).
   Web of Science ®Google Scholar
• Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 49, 1404 1413 (1997).
   Google Scholar
• Hely MA, McManis PG, Doran TJ, Walsh JC, McLeod JG. Acute optic neuritis, a prospective study of risk-factors for multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 49, 11251130 (1986).
   Google Scholar
• Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtas S, Platz P, Ryder LP. A long-term prospective study of optic neuritis, evaluation of risk factors. Ann. Neurol. 27, 386393 (1990).
   Google Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116, 117134 (1993).
   Web of Science ®Google Scholar
• Wolfson C, Confavreux C. A Markov model of the natural history of multiple sclerosis. Neuroepidemiology 4, 227239 (1985).
   Google Scholar
• Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis, a geographically based study 3. Multivariate analysis of predictive factors and models of outcome. Brain 114, 10451056 (1991).
   Google Scholar
• Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta. Neurol. Scand. 66, 355362 (1982).
   Google Scholar
• Pozzilli C, Tomassini V, Marinelli F, Paolillo A, Gasperini C, Bastianello S. Gender gap in multiple sclerosis, magnetic resonance imaging evidence. Eur. J. Neurol. 10, 9597 (2003).
   Web of Science ®Google Scholar
• Voskuhl RR, Pitchekian-Halabi H, MacKenzie-Graham A, McFarland HF, Raine CS. Gender differences in autoimmune demyelination in the mouse, implications for multiple sclerosis. Ann. Neurol. 39, 724733 (1996).
   Web of Science ®Google Scholar
• Bebo BF Jr, Schuster JC, Vandenbark AA, Offner H. Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. J. Neurosci. Res. 52, 420426 (1998).
   Web of Science ®Google Scholar
• Abramsky O. Pregnancy and multiple sclerosis. Ann. Neurol. 36(Suppl) S38S41, (1994).
   Google Scholar
• Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118, 253261 (1995).
   Web of Science ®Google Scholar
• Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339, 285 291 (1998).
   Google Scholar
• The most important study of the effects of pregnancy on multiple sclerosis.
   Google Scholar
• van Walderveen MA, Tas MW, Barkhof F et al. Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis. Neurology 44, 327329 (1994).
   Web of Science ®Google Scholar
• Verdru P, Theys P, DHoogheMB, Carton H. Pregnancy and multiple sclerosis, the influence on longterm disability. Clin. Neurol. Neurosurg. 96, 3841 (1994).
   Google Scholar
• Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 55, 848854 (2000).
   Google Scholar
• Mertin LA, Rumjanek VM. Pregnancy and the susceptibility of Lewis rats to experimental allergic encephalomyelitis. J. Neurol. Sci. 68, 1524 (1985).
   Web of Science ®Google Scholar
• Harness J, McCombe PA. The effects of pregnancy on myelin basic proteininduced experimental autoimmune encephalomyelitis in Lewis rats, suppression of clinical disease, modulation of cytokine expression in the spinal cord inflammatory infiltrate and suppression of lymphocyte proliferation by pregnancy sera. Am. J. Reprod. Immunol. 46, 405412 (2001).
   Web of Science ®Google Scholar
• Zorgdrager A, De Keyser J. Menstrually related worsening of symptoms in multiple sclerosis. J. Neurol. Sci. 149, 95 97 (1997).
   Web of Science ®Google Scholar
• Kelly MJ, Ronnekleiv OK, Ibrahim N, Lagrange AH, Wagner EJ. Estrogen modulation of K(+) channel activity in hypothalamic neurons involved in the control of the reproductive axis. Steroids 67, 447456 (2002).
   Google Scholar
• Herbison AE. Estrogen regulation of GABA transmission in rat preoptic area. Brain Res. Bull. 44, 321326 (1997).
   Web of Science ®Google Scholar
• Zorgdrager A, De Keyser J. The premenstrual period and exacerbations in multiple sclerosis. Eur. Neurol. 48, 204206 (2002).
   Web of Science ®Google Scholar
• Pozzilli C, Falaschi P, Mainero C et al. MRI in multiple sclerosis during the menstrual cycle, relationship with sex hormone patterns. Neurology 53, 622 624 (1999).
   Web of Science ®Google Scholar
• Bansil S, Lee HJ, Jindal S, Holtz CR, Cook SD. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta. Neurol. Scand. 99, 9194 (1999).
   Google Scholar
• Smith R, Studd JW. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J. R. Soc. Med. 85, 612613 (1992).
   Web of Science ®Google Scholar
• Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103, 281 300 (1980).
   Google Scholar
• Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 55, 848854 (2000).
   Google Scholar
• Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol. 105, 12961299 (1998).
   Google Scholar
• Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans, VII. Risk factors for MS. Neurology 48, 204213 (1997).
   Google Scholar
• Mosmann TR, Coffman RL. Th1 and Th2 cells, different patterns of lymphokine secretion leads to different functional properties. Ann. Rev. Immunol. 7, 145173 (1989).
   Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets, Th1, Th2 and more. Immunol. Today 17, 138146 (1996).
   Google Scholar
• Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternalfetal relationship, is successful pregnancy a TH2 phenomenon? Immunol. Today 14, 353 356 (1993).
   Google Scholar
• Mock BA, Nacy CA. Hormonal modulation of sex differences in resistance to Leishmania major systemic infections. Infect. Immun. 56, 33163319 (1988).
   Web of Science ®Google Scholar
• Huygen K, Palfliet K. Strain variation in interferon gamma production of BCGsensitized mice challenged with PPD II. Importance of one major autosomal locus and additional sexual influences. Cell Immunol. 85, 7581 (1984).
   Google Scholar
• Weinstein Y, Ran S, Segal S. Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J. Immunol. 132, 656661 (1984).
   Google Scholar
• Pelfrey CM, Cotleur AC, Lee JC, Rudick RA. Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J. Neuroimmunol. 130, 211223 (2002).
   Web of Science ®Google Scholar
• Nguyen LT, Ramanathan M, Weinstock- Guttman B, Baier M, Brownscheidle C, Jacobs LD. Sex differences in in vitro proinflammatory cytokine production from peripheral blood of multiple sclerosis patients. J. Neurol. Sci. 209, 9399 (2003).
   Google Scholar
• Allen JS, Damasio H, Grabowski TJ, Bruss J, Zhang W. Sexual dimorphism and asymmetries in the graywhite composition of the human cerebrum. Neuroimage 18, 880894 (2003).
   Google Scholar
• Allen JS, Damasio H, Grabowski TJ. Normal neuroanatomical variation in the human brain, an MRI-volumetric study. Am. J. Phys. Anthropol. 118, 341358 (2002).
   Google Scholar
• Szabo CA, Lancaster JL, Xiong J, Cook C, Fox P. MR imaging volumetry of subcortical structures and cerebellar hemispheres in normal persons. AJNR Am. J. Neuroradiol. 24, 644647 (2003).
   Google Scholar
• Szabo CA, Xiong J, Lancaster JL, Rainey L, Fox P. Amygdalar and hippocampal volumetry in control participants, differences regarding handedness. AJNR Am. J. Neuroradiol. 22, 13421345 (2001).
   Google Scholar
• Zup SL, Carrier H, Waters EM et al. Overexpression of bcl-2 reduces sex differences in neurone number in the brain and spinal cord. J. Neurosci. 23, 23572362 (2003).
   Google Scholar
• Goldstein JM, Seidman LJ, Horton NJ et al. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb. Cortex 11, 490 497 (2001).
   Web of Science ®Google Scholar
• Carrer HF, Cambiasso MJ. Sexual differentiation of the brain, genes, estrogen and neurotrophic factors. Cell. Mol. Neurobiol. 22, 479500 (2002).
   Web of Science ®Google Scholar
• Rabinowicz T, Petetot JM, Gartside PS, Sheyn D, Sheyn T, de CM. Structure of the cerebral cortex in men and women. J. Neuropathol. Exp. Neurol. 61, 4657 (2002).
   Web of Science ®Google Scholar
• Hawk T, Zhang YQ, Rajakumar G, Day AL, Simpkins JW. Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res. 796, 296298 (1998).
   Google Scholar
• Gartner J, Dehmel T, Klusmann A, Roerig P. Functional characterization of the adrenoleukodystrophy protein (ALDP) and disease pathogenesis. Endocr. Res. 28, 741 748 (2002).
   Web of Science ®Google Scholar
• Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat. Genet. 13, 472476 (1996).
   Web of Science ®Google Scholar
• Chataway J, Feakes R, Coraddu F et al. The genetics of multiple sclerosis, principles, background and updated results of the United Kingdom systematic genome screen. Brain 121, 18691887 (1998).
   Web of Science ®Google Scholar
• Chataway J, Mander A, Robertson N et al. Multiple sclerosis in sibling pairs, an analysis of 250 families. J. Neurol. Neurosurg. Psychiatry 71, 757761 (2001).
   Google Scholar
• Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13, 464468 (1996).
   Google Scholar
• Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can. J. Neurol. Sci. 19, 466471 (1992).
   Google Scholar
• Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA DR2, DQ6 haplotype in multiple sclerosis. J. Neurol. Sci. 178, 132135 (2000).
   Google Scholar
• Goris A, Heggarty S, Marrosu MG, Graham C, Billiau A, Vandenbroeck K. Linkage disequilibrium analysis of chromosome 12q1415 in multiple sclerosis, delineation of a 118kb interval around interferon- (IFNG) that is involved in male versus female differential susceptibility. Genes Immun. 3, 470476 (2002).
   Web of Science ®Google Scholar
• Warren SA, Warren KG. Influence of gender on susceptibility to multiple sclerosis and age of onset in concordant sibships. Int. J. Epidemiol. 25, 142145 (1996).
   Web of Science ®Google Scholar
• Sadovnick AD, Bulman DE, Hashimoto L, DHoogheMB, Ebers GC. The influence of gender on the susceptibility to multiple sclerosis in sibships. Arch. Neurol. 48, 586 588 (1991).
   Google Scholar
• Okuda Y, Okuda M, Bernard CC. Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol. Lett. 81, 2529 (2002).
   Google Scholar
• Elenkov IJ, Wilder RL, Bakalov VK et al. IL-12, TNF- and hormonal changes during late pregnancy and early postpartum, implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 86, 49334938 (2001).
   Google Scholar
• Bebo BF Jr, Zelinka-Vincent E, Adamus G, Amundson D, Vandenbark AA, Offner H. Gonadal hormones influence the immune response to PLP 139151 and the clinical course of relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 84, 122130 (1998).
   Google Scholar
• Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T-helper 2 bias in the autoantigen-specific T-lymphocyte response. J. Immunol. 159, 36 (1997).
   Google Scholar
• Bebo BF Jr, Adlard K, Schuster JC, Unsicker L, Vandenbark AA, Offner H. Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. J. Neurosci. Res. 55, 432440 (1999).
   Google Scholar
• Offner H, Zamora A, Drought H et al. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsingremitting EAE. J. Neuroimmunol. 130, 128139 (2002).
   Web of Science ®Google Scholar
• McCombe PA, Nickson I, Tabi Z, Pender MP. Apoptosis of V 8.2+ T-lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J. Neurol. Sci. 139, 16 (1996).
   Google Scholar
• Pender MP, McCombe PA, Yoong G, Nguyen KB. Apoptosis of Tlymphocytes in the nervous system in experimental autoimmune encephalomyelitis, its possible implications for recovery and acquired tolerance. J. Autoimmun. 1992 5, 401410.
   Web of Science ®Google Scholar
• Dulos GJ, Bagchus WM. Androgens indirectly accelerate thymocyte apoptosis. Int. Immunopharmacol. 1, 321328 (2001).
   Web of Science ®Google Scholar
• Vermeulen A. Ageing, hormones, body composition, metabolic effects. World J. Urol. 20, 2327 (2002).
   Web of Science ®Google Scholar
• Voskuhl RR, Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis, implications for multiple sclerosis. Neuroscientist 7, 258 270 (2001).
   Web of Science ®Google Scholar
• Good review of the role of sex hormones in multiple sclerosis.
   Google Scholar
• Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease, implications for multiple sclerosis. Neurology 52, 12301238 (1999).
   Google Scholar
• Subramanian S, Matejuk A, Zamora A, Vandenbark AA, Offner H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL Mice and inhibits the recruitment of inflammatory cells into the central nervous system. J. Immunol. 170, 15481555 (2003).
   Google Scholar
• Liu HY, Buenafe AC, Matejuk A et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70, 238248 (2002).
   Web of Science ®Google Scholar
• Ito A, Buenafe AC, Matejuk A et al. Estrogen inhibits systemic T-cell expression of TNF- and recruitment of TNF-(+) Tcells and macrophages into the CNS of mice developing experimental encephalomyelitis. Clin. Immunol. 102, 275282 (2002).
   Web of Science ®Google Scholar
• Matejuk A, Dwyer J, Zamora A, Vandenbark AA, Offner H. Evaluation of the effects of 17 -estradiol (17 -e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 143, 313319 (2002).
   Google Scholar
• Matejuk A, Adlard K, Zamora A, Silverman M, Vandenbark AA, Offner H. 17 - estradiol inhibits cytokine, chemokine and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J. Neurosci. Res. 65, 529542 (2001).
   Google Scholar
• Sicotte NL, Liva SM, Klutch R et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421428 (2002).
   Web of Science ®Google Scholar
• Trial showing that estriol may be beneficial in multiple sclerosis.
   Google Scholar
• Tornwall J, Carey AB, Fox RI, Fox HS. Estrogen in autoimmunity, expression of estrogen receptors in thymic and autoimmune T-cells. J. Gend. Specif. Med. 2, 3340 (1999).
   Google Scholar
• McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57, 357 384 (2002).
   Google Scholar
• Arnason BG, Richman DP. Effect of oral contraceptives on experimental demyelinating disease. Arch. Neurol. 21, 103108 (1969).
   Google Scholar
• Hoffman GE, Le WW, Murphy AZ, Koski CL. Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rats. Exp. Neurol. 171, 272284 (2001).
   Web of Science ®Google Scholar
• Morton H, Cavanagh AC, Athanasas- Platsis S, Quinn KA, Rolfe BE. Early pregnancy factor has immunosuppressive and growth factor properties. Reprod. Fertil. Dev. 4, 411422 (1992).
   Google Scholar
• Zhang B, Harness J, Somodevilla-Torres MJ et al. Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139151. J. Neurol. Sci. 182, 515 (2000).
   Google Scholar
• Zhang B, Walsh NM, Nguyen KB et al. Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. J. Neuol. Sci. (2003) (In Press).
   Google Scholar
• Martal JL, Chene NM, Huynh LP et al. IFN-tau, a novel subtype I IFN-1. Structural characteristics, nonubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 80, 755777 (1998).
   Google Scholar
• Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis, a systematic review. Lancet 361, 545552 (2003).
   Web of Science ®Google Scholar
• Soos JM, Stuve O, Youssef S et al. Cutting edge, oral Type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J. Immunol. 169, 2231 2235 (2002).
   Google Scholar
• Mujtaba MG, Streit WJ, Johnson HM. IFN-tau suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. Cell Immunol. 186, 94 102 (1998).
   Google Scholar
• Langer-Gould A, Garren H, Slansky A, Ruiz PJ, Steinman L. Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis, evidence for a suppressive pregnancy-related serum factor. J. Immunol. 169, 10841091 (2002).
   Google Scholar
• Brenner T, Evron S, Soffer D, Abramsky O. Treatment of experimental allergic encephalomyelitis in rabbits with - fetoprotein. Isr. J. Med. Sci. 21, 945949 (1985).
   Google Scholar
• Abramsky O, Brenner T, Mizrachi R, Soffer D. -fetoprotein suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. 2, 17 (1982).
   Web of Science ®Google Scholar
• Kikukawa A, Peterson BS, Deutsch HF. Attempts to suppress experimental allergic encephalomyelitis in rats with - fetoprotein. Tumour Biol. 9, 8494 (1988).
   Google Scholar
• Caspary EA, Hughes D. Experimental allergic encephalomyelitis in the guinea-pig. Failure to suppress with crude human chorionic gonadotrophin. J. Neurol. Sci. 34, 5362 (1977).
   Google Scholar
• McCombe PA, Nickson I, Tabi Z, Pender MP. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V 8.2+ and myelin basic proteinreactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V 8.2+ cells. J. Neuroimmunol. 70, 93101 (1996).
   Google Scholar
• Potau N, Ibanez L, Sentis M, Carrascosa A. Sexual dimorphism in the maturation of the pituitarygonadal axis, assessed by GnRH agonist challenge. Eur. J. Endocrinol. 141, 2734 (1999).
   Web of Science ®Google Scholar
• Liu X, Yao DL, Webster H. Insulin-like growth Factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult. Scler. 1, 29 (1995).
   Google Scholar
• Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci. 58, 13011306 (1996).
   Web of Science ®Google Scholar
• Cannella B, Pitt D, Capello E, Raine CS. Insulin-like growth factor-1 fails to enhance CNS myelin repair during autoimmune demyelination. Am. J. Pathol. 157, 933 943 (2000).
   Google Scholar
• The IFN- B Multiple Sclerosis Study Group. Interferon -1b is effective in relapsingremitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43, 655661 (1993).
   Google Scholar
• Paty DW, Li DK. Interferon -1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results: a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN-B Multiple Sclerosis Study Group. Neurology 43, 662 667 (1993).
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon -1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285294 (1996).
   Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon -1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon -1a in relapsing/remitting multiple sclerosis. Lancet 352, 14981504 (1998).
   Google Scholar
• Simon JH, Jacobs LD, Campion M et al. Magnetic resonance studies of intramuscular interferon -1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol. 43, 7987 (1998).
   Google Scholar
• Randomized controlled trial of interferon--1a in secondary progressive MS, clinical results. Neurology 56, 14961504 (2001).
   Google Scholar
• Hughes RA. Interferon--1a for secondary progressive multiple sclerosis. J. Neurol. Sci. 206, 199202 (2003).
   Google Scholar
• Leary SM, Thompson AJ. Interferon--1a in primary progressive multiple sclerosis. J. Neurol. Sci. 206, 215216 (2003).
   Google Scholar
• Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis, a systematic review. Arch. Intern. Med. 162, 21612169 (2002).
   Google Scholar
• Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis, a systematic review. Lancet 361, 545552 (2003).
   Web of Science ®Google Scholar
• Parry A, Corkill R, Blamire AM et al. - interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J. Neurol. 250, 171178 (2003).
   Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis, results of a Phase III multicenter, double-blind placebocontrolled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 45, 12681276.
   Google Scholar
• Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. The Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6, 255266 (2000).
   Google Scholar
• Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G. Copaxones effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 59, 12841286 (2002).
   Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/ Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290297 (2001).
   Google Scholar
• Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF, implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125, 23812391 (2002).
   Google Scholar
• Paolillo A, Coles AJ, Molyneux PD et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53, 751757 (1999).
   Web of Science ®Google Scholar
• Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344, 298301 (1994).
   Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 1523 (2003).
   Web of Science ®Google Scholar
• Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol. 243, 2528 (1996).
   Web of Science ®Google Scholar
• Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult. Scler. 6\(Suppl. 2), S18S33 (2000).
   Google Scholar